1092540-88-9

Basic information

• Product Name: C₃₁H₂₇F₃N₄O₃
• Synonyms: C₃₁H₂₇F₃N₄O₃
• CAS NO: 1092540-88-9
• Molecular Weight: 560.576
• Mol File: 1092540-88-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: C₃₁H₂₇F₃N₄O₃(CAS DataBase Reference)
• NIST Chemistry Reference: C₃₁H₂₇F₃N₄O₃(1092540-88-9)
• EPA Substance Registry System: C₃₁H₂₇F₃N₄O₃(1092540-88-9)

Safety Data

• Hazardous Substances Data: 1092540-88-9(Hazardous Substances Data)

Upstream product

• 100-16-3 4-nitrophenylhydrazone 
• 15389-33-0 4,4,4-Trifluoro-1-phenanthren-2-yl-butane-1,3-dione 
• 5960-69-0 2-acetylphenanthrene 
• 1100051-52-2 C₂₄H₁₄F₃N₃O₂ 
• 882854-64-0 4-(5-phenanthren-2-yl-3-trifluoromethyl-pyrazol-1-yl)-phenylamine 
• 51779-32-9 iminodicarboxylic acid di-tert-butyl ester 
• 4530-20-5 BOC-glycine 

Downstream Products

• 742112-33-0 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}acetamide 

Relevant articles and documents

Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus

Methicillin-resistant Staphylococcus aureus (MRSA) poses a serious threat to public health because of its resistance to multiple antibiotics most commonly used to treat infection. In this study, we report the unique ability of the cyclooxygenase-2 (COX-2) inhibitor celecoxib to kill Staphylococcus aureus and MRSA with modest potency. We hypothesize that the anti-Staphylococcus activity of celecoxib could be pharmacologically exploited to develop novel anti-MRSA agents with a distinct mechanism. Examination of an in-house, celecoxib-based focused compound library in conjunction with structural modifications led to the identification of compound 46 as the lead agent with high antibacterial potency against a panel of Staphylococcus pathogens and different strains of MRSA. Moreover, this killing effect is bacteria-specific, as human cancer cells are resistant to 46. In addition, a single intraperitoneal administration of compound 46 at 30 mg/kg improved the survival of MRSA-infected C57BL/6 mice. In light of its high potency in eradicating MRSA in vitro and its in vivo activity, compound 46 and its analogues warrant continued preclinical development as a potential therapeutic intervention against MRSA.

PDK-1/AKT SIGNALING INHIBITORS

A new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of formula (I): wherein X is selected from the group consisting of alkyl and haloalkyl; Ar is an aryl radical selected from the group consisting of phenyl, biphenyl, naphthyl, anthryl,